A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

BACKGROUND: Mirikizumab (miri) improved symptom control in a Phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study at Week (W)12, in patients (pts) with moderately-to-severely active ulcerative colitis (UC; LUCENT-1). PURPOSE: This analysis assessed sustained s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dignass, A, Danese, S, Matsuoka, K, Ferrante, M, Long, M, Redondo, I, Gibble, T H, Moses, R, Li, X, Morris, N, Milch, C, Abreu, M, Jones, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991200/
http://dx.doi.org/10.1093/jcag/gwac036.185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991200/
http://dx.doi.org/10.1093/jcag/gwac036.185

Ejemplares similares